Download MendeleyStructure-Guided Design of a Brain-Penetrant Covalent Inhibitor of Human Butyrylcholinesterase with In Vivo Procognitive Efficacy.
Mastnak-Sokolov, P., Kosak, U., Meden, A., Knez, D., Zakelj, S., Horvat, S., Pislar, A., Kljun, J., Igert, A., Dias, J., Nachon, F., Brazzolotto, X., Novak, M., Rydlova, V., Karasova, J.Z., Soukup, O., Manik, A., Detka, J., Salat, K., Gobec, S.(2026) J Med Chem 69: 22506-22538
- PubMed: 42917927 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.6c01737
- Primary Citation Related Structures:
30GX, 30GY - PubMed Abstract:
Butyrylcholinesterase (BChE) has emerged as a validated therapeutic target for the management of Alzheimer's disease symptoms, particularly in advanced stages when acetylcholinesterase activity declines. Despite the numerous BChE inhibitors reported, only the cymserine derivative bisnorcymserine has progressed to clinical evaluation. Here, we report the design and characterization of a novel selective human BChE (hBChE) inhibitor, N-benzylpyrrolidine carbamate (S)-(+)-14. Kinetic analyses and X-ray crystallography of the hBChE-inhibitor complex confirm a covalent mechanism of inhibition. Compound (S)-(+)-14 demonstrates favorable metabolic stability and achieves brain exposure following intraperitoneal administration in mice. In a scopolamine-induced cognitive impairment model, (S)-(+)-14 improves cognitive performance without causing cholinergic adverse effects or motor deficits. Collectively, these findings identify (S)-(+)-14 as a structurally validated, brain-penetrant covalent hBChE inhibitor and highlight its promise as a lead compound for the treatment of Alzheimer's disease.
- Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000Ljubljana, Slovenia.
Organizational Affiliation:
